Antiviral drugs for prophylaxis and treatment of influenza

Medical Letter on Drugs and Therapeutics

Volumn 48, Issue 1246, 2006, Pages 87-88

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; FLULAVAL; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR; ACETAMIDE DERIVATIVE; GUANIDINE DERIVATIVE; PYRAN DERIVATIVE; SIALIC ACID DERIVATIVE;

AVIAN INFLUENZA; BRONCHOSPASM; COUGHING; DISEASE CONTROL; DISEASE DURATION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG COST; HEADACHE; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; NAUSEA; NOSE DISEASE; PROPHYLAXIS; SHORT SURVEY; SIDE EFFECT; THROAT DISEASE; VIRUS RESISTANCE; VOMITING; ANIMAL; REVIEW;

ACETAMIDES; ANIMALS; ANTIVIRAL AGENTS; GUANIDINES; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; OSELTAMIVIR; PYRANS; SIALIC ACIDS; ZANAMIVIR;

EID: 33750938884     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (16)

1. RA Bright et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891.
2. Advisory Committee on Immunization Practices. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55 (RR-10):1.
3. Centers for Disease Control and Prevention. Update: Influenza activity - United States and worldwide. May 21-September 9, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:1021.
4. A Moscona. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363.
5. N Kawai et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43:439.
6. L Kaiser et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160:3234.
7. L Kaiser et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667.
8. A Moscona. Oseltamivir resistance - disabling our influenza defenses. N Engl J Med 2005; 353:2633.
9. M Kiso et al. Resistant influenza A viruses in children treated with oseltamivir: Descriptive study. Lancet 2004; 364:759.
10. F Hayden et al. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir Ther 2005; 10:873.
11. JC Williamson and PS Pegram. Neuraminidase inhibitors in patients with underlying airways disease. Am J Respir Med 2002; 1:85.
12. Influenza vaccine 2006-2007. Med Lett Drugs Ther 2006; 48:81.
13. IA Leneva et al. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000; 48:101.
14. MD de Jong et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667.
15. QM Le. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005; 437:1108.
16. JH Beigel et al. The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) Infection in Humans. N Engl J Med 2005; 353:1374.